Fig. 2: Functional assessment of hIL-5-anchored CCAR-cells in vivo. | Cell Discovery

Fig. 2: Functional assessment of hIL-5-anchored CCAR-cells in vivo.

From: Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells

Fig. 2

a flow cytometry analysis of the CD69 expression on the CCAR-Jurkat cells 3 h or 6 h after the NCG mice were injected intraperitoneally with hIL-5RΞ±+ U2OS cells and hIL-5-anchored CCAR-Jurkat cells. Two-tailed t-test, *P < 0.05. b Representative bioluminescence images showing the target cell burden in the NCG mice 24 h after the hIL-5RΞ±+ U2OS cells expressing firefly luciferase and the murine primary CCAR-T cells/UTD-T cells were intraperitoneally injected. c The quantification of the target cell burden in mice from b. Two-tailed t-test, ****P < 0.0001. d Representative bioluminescence images showing the target cell burden in the NCG mice 24 h after the hIL-5RΞ±+ U2OS cells expressing firefly luciferase and the human primary CCAR-T cells/UTD-T cells were intraperitoneally injected. e The quantification of the target cell burden in mice from d. Two-tailed t-test, ***P < 0.001.

Back to article page